MaRS Innovation provided crucial commercialization funding to support research from The Hospital for Sick Children
MaRS Innovation (MI) and The Hospital for Sick Children (SickKids) have launched OtoSim Inc. to commercialize an otoscopy training system and process developed by two otolaryngologists at SickKids.
The new product, the OtoSim™ program and training device, is the first in a series of training systems directed at improving the accuracy of ear examinations. Using simulation-based training is part of a wider trend in medicine.
In otoscopy, healthcare professionals ...
Toronto’s (U of T)
Funds secured from MaRS Innovation, HTX, OICR and CCR to speed commercialization of Xagenic's rapid molecular diagnostic technology
TORONTO (October 13, 2010) – MaRS Innovation today announced a $500,000 investment in its Toronto-based spin-off company, Xagenic Inc.
When combined with funds from other investors and lenders, the new working capital provided to Xagenic totals $1.04 million.
This follow‐on financing includes a $300,000 loan from HTX, The Health Technology Exchange; $200,000 from the Ontario Institute for Cancer Research; $40,000 from the Ontario Centre of Excellence ...
TORONTO (June 30, 2009) – MaRS Innovation (MI) and the University of Toronto (U of T) are pleased to announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers.
“There are 300 million diabetics worldwide, of which some 15 per cent develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialization opportunity that MaRS Innovation has identified as being a potential win for some ...